Hickey R, Knape K G, Blanchard J, Hoffman J, Ramamurthy S
Department of Anesthesiology, University of Texas Health Science Center, San Antonio 78284.
Reg Anesth. 1990 Jul-Aug;15(4):194-8.
To determine the effect of carbonation of lidocaine, a comparison of 1.0% lidocaine hydrochloride (HCl) and 1.1% lidocaine hydrocarbonate (CO2), both with 1:200,000 epinephrine, was made in this study of 50 patients receiving interscalene brachial plexus blocks. Sensory block was determined by the response to pinprick in the C2-T2 dermatomes, while motor block was assessed by the development of paresis and paralysis at the shoulder and hand. The percentage of patients developing analgesia (decreased sensation to pinprick) and anesthesia (total absence of sensation to pinprick) at each dermatome level as well as the percentage of patients developing motor block was not significantly different between the two forms of lidocaine. The initial onset of analgesia [lidocaine HCl, 4.0 +/- 2.4 (SD) minutes; lidocaine CO2, 4.3 +/- 3.8 (SD) minutes] and anesthesia [lidocaine HCl, 10.1 +/- 5.7 (SD) minutes; lidocaine CO2, 7.8 +/- 4.4 (SD) minutes] did not differ significantly between the two groups. At the individual dermatomes, there was no difference in the onset of analgesia except at one dermatome level, C7, which was near the level of local anesthetic injection. Anesthesia onset in each dermatome as well as the onset of motor block did not differ between the two groups. It is concluded that lidocaine CO2 does not offer any significant clinical advantage over lidocaine HCl in interscalene brachial plexus block.
为确定利多卡因碳酸化的效果,本研究对50例接受肌间沟臂丛神经阻滞的患者进行了比较,将1.0%盐酸利多卡因(HCl)和1.1%碳酸利多卡因(CO2)均与1:200,000肾上腺素合用。通过对C2 - T2皮节针刺的反应来确定感觉阻滞,而通过肩部和手部无力及麻痹的出现来评估运动阻滞。两种形式的利多卡因在每个皮节水平产生镇痛(针刺感觉减退)和麻醉(针刺感觉完全消失)的患者百分比以及产生运动阻滞的患者百分比并无显著差异。两组之间镇痛的初始起效时间[盐酸利多卡因,4.0±2.4(标准差)分钟;碳酸利多卡因,4.3±3.8(标准差)分钟]和麻醉的初始起效时间[盐酸利多卡因,10.1±5.7(标准差)分钟;碳酸利多卡因,7.8±4.4(标准差)分钟]并无显著差异。在各个皮节,除了在靠近局部麻醉剂注射水平的一个皮节水平(C7)外,镇痛的起效时间并无差异。两组之间每个皮节的麻醉起效时间以及运动阻滞的起效时间并无差异。得出的结论是,在肌间沟臂丛神经阻滞中,碳酸利多卡因相较于盐酸利多卡因并无任何显著的临床优势。